Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $42
Express News | Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute's Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $34